Alchemab Therapeutics

Alchemab Therapeutics develops antibody therapeutics for hard-to-treat diseases by identifying resilient individuals, such as long-term cancer survivors, who resist or overcome illness. The company uses deep learning and adaptive immunity analysis to create treatments based on antibodies found across these resilient populations. Its clinical pipeline focuses on next-generation human-derived antibodies for the biopharma market.